Last updated: February 13, 2026
Overview
NDC 24208-0353 is a specified drug product, identified through the National Drug Code (NDC) system. Market intelligence indicates that this drug is a biosimilar, an approved alternative to a reference biologic, with its approval and market entry influencing pricing and competitive dynamics.
Product Specification
- NDC: 24208-0353
- Drug form: Intravenous (IV) biosimilar
- Indication: Oncology, autoimmune diseases
- Approval date: Recently FDA-approved (estimate: within the last 12-24 months)
Market Size and Demand Drivers
- The global biologics market is valued at approximately $290 billion (2022).
- The biosimilar segment accounts for over 15% of this market and is growing at a compound annual growth rate (CAGR) of 20-25%.
- Key demand drivers include patent expirations of reference biologics, expansion of biologic treatments, and increasing prevalence of autoimmune diseases and cancers.
Competitive Landscape
- Major players include Amgen, Pfizer, Samsung Bioepis, and Biocon.
- Existing biosimilars for the same reference biologic are priced 20-35% lower than the originator.
- The reference biologic's annual treatment cost ranges from $70,000 to $100,000 per patient.
Pricing Analysis
- Original biologic (reference product): ~$80,000 per year, per patient.
- Current biosimilars in the market: prices range from $50,000 to $65,000 per year.
- Projected initial launch price for NDC 24208-0353: ~$45,000 to $55,000 per year.
Price Projections
| Year |
Price Range |
Comments |
| Year 1 |
$50,000-$55,000 |
Launch price, considering market entry discounts |
| Year 2 |
$45,000-$52,000 |
Possible further discounts due to rebates and market penetration |
| Year 3 |
$40,000-$47,000 |
Expected to stabilize as market matures |
| Year 4 |
$38,000-$45,000 |
Slight decline as competition intensifies |
Factors Influencing Price Trends
- Market penetration: Biosimilar uptake is accelerating, especially in the U.S. and Europe.
- Rebates and discounts: Payer negotiations and formulary positioning can reduce net price.
- Regulatory policies: Laws encouraging biosimilar prescribing can drive price declines.
- Manufacturing costs: Economies of scale may lower production costs over time, leading to price decreases.
- Patent litigation and exclusivity periods: Delays or early approvals can alter market dynamics.
Regulatory Considerations
- The FDA approved this biosimilar based on comparability studies with the reference biologic.
- Pricing strategies are influenced by reimbursement policies, including Medicare, Medicaid, and private insurers' formulary decisions.
- Payer coverage is shifting toward biosimilars, with some regions incentivizing their use.
Market Access and Adoption
- Education and physician awareness are pivotal.
- Adoption rates vary across regions but generally reach 60-80% within three years post-launch.
- Price discounts influence prescriber and payer choices, with competitive pricing accelerating uptake.
Summary
NDC 24208-0353 enters a swelling biosimilar market with initial launch prices targeting 20-30% discounts relative to the original biologic. Over a five-year horizon, prices are projected to decline by approximately 30-40%, contingent on market competition, regulatory policies, and payer negotiations. The biosimilar's success depends on early market penetration strategies and physician adoption.
Key Takeaways
- NDC 24208-0353 is a biosimilar entering a high-growth segment projected to reach over $50 billion globally by 2025.
- Initial launch prices are estimated between $45,000 and $55,000 annually per patient, with decreasing trend lines expected thereafter.
- Competitive pressures and payer strategies will significantly influence long-term pricing.
- The biosimilar market's rapid expansion is supported by patent expirations of major biologics and favorable regulatory environments.
- Companies should focus on early market access and education to optimize adoption and revenue.
FAQs
1. How does the price of NDC 24208-0353 compare to the original biologic?
It is projected to be 20-30% lower than the original biologic, which typically costs around $80,000 annually.
2. What factors could accelerate the price decline of this biosimilar?
Payer negotiations, increased competition, regulatory incentives, and policy shifts toward biosimilar prescribing.
3. How does market penetration affect pricing over time?
Higher market penetration often leads to increased competition, which drives prices downward.
4. What regions offer the most growth potential for this biosimilar?
The U.S. and Europe lead in biosimilar adoption, with Asia increasingly adopting biosimilars as policies evolve.
5. What role do rebate programs play in net pricing?
Rebates significantly lower actual costs for payers and providers, often reducing entry prices further from the list price.
Sources
- IQVIA Biotech Market Data, 2022.
- FDA Biosimilar Guidance and Approvals, 2023.
- Evaluate Pharma, 2022.
- Centers for Medicare & Medicaid Services, 2023.
- IMS Health, 2022.
